Treos Bio to Present New Clinical Data on Off-the-Shelf Peptide Immunotherapy for Colorectal Cancer at 2024 ASCO Annual Meeting
May 08, 2024 07:45 ET
|
Treos Bio Corp.
LONDON and BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Treos Bio, a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision peptide immunotherapies, said...
Fight Colorectal Cancer Launches ChatCRC: An AI-Powered Chatbot Revolutionizing Colorectal Cancer Support
May 01, 2024 13:04 ET
|
Fight Colorectal Cancer
Springfield, Mo., May 01, 2024 (GLOBE NEWSWIRE) -- Fight Colorectal Cancer (Fight CRC), a leading advocacy organization dedicated to supporting colorectal cancer patients and caregivers, is proud to...
Biomerica and Leading UAE Healthcare Company Forge a Path to Enhanced Colorectal and Breast Screening with Exclusive Multi-Year Distribution Agreement
April 29, 2024 08:19 ET
|
Biomerica, Inc.
Dubai Healthcare Authority Granted Insurance Reimbursement for Biomerica’s EZ Detect™ Colon Disease Screening Test EZ Detect™ is a simple FDA cleared 2-minute at-home test that detects early warning...
Theratechnologies présente des données précliniques au congrès 2024 de l’AACR qui met en évidence la polyvalence et la flexibilité de la plateforme technologique d’oncologie SORT1+(MC)
April 08, 2024 16:30 ET
|
Theratechnologies
Les nouveaux conjugués camptothécine-peptide sont bien tolérés et associés à une régression tumorale marquée dans les modèles de xénogreffe de cancer colorectal et de cancer du sein triple...
Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform
April 08, 2024 16:30 ET
|
Theratechnologies
Novel camptothecin-peptide conjugates are well tolerated and associated with significant tumor regression in colorectal cancer and triple-negative breast cancer xenograft modelsSORT1 gene silencing...
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
April 08, 2024 16:05 ET
|
Cardiff Oncology, Inc.
RAS-mutated mCRC – In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor’s ability to adapt to hypoxia resulting in a significant decrease in both tumor...
Larkspur Biosciences to Present New Preclinical Research on Lead Development Program Candidate, a First-in-Class PIP4K2C Protein Degrader, at AACR 2024
March 28, 2024 08:00 ET
|
Larkspur Biosciences, Inc.
Larkspur Biosciences to Present New Preclinical Research on Lead Development Program Candidate, a First-in-Class PIP4K2C Protein Degrader, at AACR 2024
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
March 27, 2024 08:00 ET
|
Immuneering Corporation
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
Community Oncology Services Global Market Report 2024
March 21, 2024 18:54 ET
|
Research and Markets
Dublin, March 21, 2024 (GLOBE NEWSWIRE) -- The "Community Oncology Services Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The community oncology services...
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
March 21, 2024 09:00 ET
|
Compass Therapeutics
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update